9.5 0.23 (2.48%) | 11-22 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 11.68 | 1-year : | 13.64 |
Resists | First : | 10 | Second : | 11.68 |
Pivot price | 9.92 | |||
Supports | First : | 9.9 | Second : | 9.85 |
MAs | MA(5) : | 9.95 | MA(20) : | 9.94 |
MA(100) : | 9.94 | MA(250) : | 10 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 53.8 | D(3) : | 58.9 |
RSI | RSI(14): 51.8 | |||
52-week | High : | 10.64 | Low : | 9.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FLACU ] has closed below upper band by 42.0%. Bollinger Bands are 29.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 9.97 - 10.02 | 10.02 - 10.06 |
Low: | 9.82 - 9.88 | 9.88 - 9.93 |
Close: | 9.86 - 9.94 | 9.94 - 10.02 |
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
Thu, 13 Jul 2023
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus - Nasdaq
Wed, 09 Dec 2020
Record IPO & SPAC Bubble Fattened by Ridiculous DoorDash IPO. Airbnb Next - WOLF STREET
Wed, 09 Dec 2020
Biotech SPAC Frazier Lifesciences Acquisition prices upsized $120 million IPO at $10 - Renaissance Capital
Wed, 09 Dec 2020
Frazier Lifesciences Acquisition Corporation Announces Pricing of Upsized $120 Million Initial Public Offering - Business Wire
Tue, 24 Nov 2020
A SPAC called FLAC? Seattle venture capital firm to launch $100 million 'blank check' company - GeekWire
Fri, 20 Nov 2020
US IPO Weekly Recap: Breast cancer biotech pops 158% in a 6 IPO week - Renaissance Capital
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Financial Services
|
|
Industry:
Shell Companies
|
|
Shares Out | 0 (M) |
Shares Float | 14 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 61.9 (%) |
Shares Short | 1 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.41 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -2 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -24.25 |
Price to Sales | 0 |
Price to Cash Flow | -0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |